Stéphane Bancel, Moderna CEO (Christopher Goodney/Bloomberg via Getty Images)

Mod­er­na spells out rare dis­ease am­bi­tions: 'We have a bunch of INDs planned'

Mod­er­na said in June that it was “qua­dru­pling down” on rare dis­ease. Right now, that looks like nine or so INDs in the plan­ning phase and po­ten­tial­ly “many more com­ing af­ter,” ac­cord­ing to head of de­vel­op­ment for ther­a­peu­tics and on­col­o­gy Kyle Holen.

The pub­lic fo­cus at Mod­er­na has been trained on RSV and the chal­lenges of shift­ing out of a pan­dem­ic mar­ket for Covid-19. The com­pa­ny has re­peat­ed­ly said there’s much more it wants to do with mR­NA be­yond vac­cines, in­clud­ing us­ing it to sup­ply the ge­net­ic code for miss­ing or bro­ken pro­teins that dri­ve rare dis­ease. But ex­ec­u­tives have kept their cards rel­a­tive­ly close.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.